SUMMARY In a 1-day, 1-dose, double-masked, randomised trial, with each of 12 patients acting as his/her own control, atenolol drops 4% (a selective 31-adrenergic blocker) produced a significantly greater fall in ocular tension measured by applanation than did adrenaline drops 1 % (P <0-01 Wilcoxon matched pairs signed ranks test). The mean differences, which favoured atenolol, between the falls in pressure produced by these 2 drugs at 1x5 hours, 3x5 hours, 5x5 hours, and 7 hours after instillation of the drops was 2 1, 4-6, 4 0, and 3-6 mmHg, respectively. Long-term studies would be required before any conclusion was justified about the relative merits of these 2 drugs in the treatment of glaucoma.
against standard remedies such as pilocarpine and adrenaline and, of course, against each other would be of considerable interest. Also, in glaucoma treatment these drugs alone are probably unlikely to be powerful enough, so that their effect in combination with other established drugs is worth studying. Possibly the most theoretically interesting first drug for comparison, and also for study as a combinant, would be the traditional adrenaline drops 1 %.
Adrenaline (epinephrine) eye drops have an established place in the treatment of chronic simple glaucoma (noradrenaline also reduces ocular tension), which seems to result from a decrease in production of aqueous humour and an increased outflow (Duke-Elder, 1969 ).
Aim of investigation
One question is posed and one hypothesis is tested in this investigation.
The question: Is there a significant difference between the ocular hypotensive effect of atenolol drops 4% and adrenaline drops 1 %?
The hypothesis: Adrenaline drops (x, f1, and P2 stimulator) reduce ocular tension, yet atenolol, which is a selective ,3l-adrenergic blocker, also 296 Atenolol versus adrenaline eye drops and an evahiation of these two combined reduces ocular tension. The apparent conflict would be resolved if the P, stimulation of adrenaline were an ocular hypertensive factor, swamped by adrenaline's oc-and 32-agonistic effects which are hypotensive-the net effect of adrenaline being hypotensive. If that hypothesis were valid, atenolol drops given, say, half an hour before adrenaline drops should result in a greater hypotensive effect than would be produced by either alone and greater than the effect of the combination in reverse order, that is, adrenaline before atenolol. The effect of adrenaline before atenolol should be little better than the effect of adrenaline alone. (adrenaline 1 % BP). The same drops were used as first instillation in the comparison atenolol versus adrenaline but in each case were followed 30 minutes later by saline drops 0 9 %. Thus patient and tonometrist could not distinguish the 4 test days, but unusual taste might suggest 'active' drops (saline drops and atenolol drops produce the same ocular discomfort, that is, negligible).
Although the label which designated the bottle's contents was obscured by another which stated only the patient's name and specified the test day and the order of instillation (first or second), it was possible to deduce the bottle's contents from the shape or stopper. We decided not to risk inactivation of adrenaline by decanting it into a standard bottle, and so a separate technician instilled the treatment, the tonometrist thereby remaining 'masked'. A disposable dropper was used for each instillation in order to achieve a standard volume.
All antiglaucoma medication was stopped 36 hours before each test day. Between test days patients continued their usual treatment.
The order in which the 4 pairs of treatments (atenolol-then-adrenaline, adrenaline-then-atenolol, atenolol-then-saline, and adrenaline-then-saline) were given was decided by a Latin square design, chosen to balance the residual effect of previous test treatment as well as to allow for any tendency in diurnal pressure variations to change with time. Patients entered the trial in 3 blocks of 4 patients each. The complete design is shown in Table 2 .
The order of paired treatments so decided for each of the 12 patients was written on slips of paper. The 4 slips for each patient were placed in an envelope, which remained sealed until a patient entered the trial, when the seal was broken and the series of bottles for that patient were labelled.
No vehicle (or placebo) day has been included in order to minimise the number of patients required to maintain a balanced design and also to avoid the need for patients to attend for a fifth test day.
STATISTICAL
In the planning of the experiment it was considered that a difference of 3 mmHg or more would be important in the atenolol versus adrenaline study. Twelve patients were necessary to provide data which, on analysis, would be powerful enough (power: at least 80 %,) to detect that difference at a significant level (P<0 05). Calculation of trial size was based on historical data from controlled studies at the Princess Alexandra Eye Pavilion. This prior information suggested that differences were distributed with variance of 12 mmHg2. The anticipated difference due to order of administration atenololthen-adrenaline versus adrenaline-then-atenolol was assumed to be less than 3 mmHg, so that our chance of detecting it with 12 patients was therefore less. (To detect a difference of 2 mmHg with power 80% would require 24 patients; a difference of 1 mmHg 96 patients.)
For each patient the pressure change (compared with the 09.00 h reference pressure) at 10.30, 12.30, 14.30, and 16 .00 h has been calculated. For patients with symmetrical glaucoma (Nos. 1, 5, 6 to 12) the mean R and L change in pressure has been used, that is, pressure change at time, t, has been defined as:
(P<0 01, Wilcoxon matched pairs signed ranks test). Median difference in overall pressure fall was 2x3 mmHg (mean difference 3-6 mmHg). The variance has been estimated as 11 -8 mmHg2, in close agreement with our prior information, but in the analysis a normal distribution of the difference has not been assumed.
Might a chance difference in the 09.00 h reference pressure favour the atenolol day? Fig. 3 shows that there is little difference between reference pressures on these 2 test days and there is no consistent bias towards 1 drug.
We plotted the overall pressure fall against thelogarithm of the 09.00 h reference pressure. In the case of atenolol, the former increased linearly with the latter, whereas in the case of adrenaline there was only a slight indication of linearity.
(09.00 h pressure in R -pressure at time, t, in R) + (09.00 h pressure in L -pressure at time, t, in L) It was disappointing to find no significant differencebetween overall pressure falls produced by atenololthen-adrenaline, compared with falls produced by adrenaline-then-atenolol. Furthermore, no adjuvant effect has been observed, rather the reverse.
Atenolol alone, however, was significantly better than atenolol followed by adrenaline (P<0.02, Wilcoxon matched pairs signed ranks test), and (pressure fall at 10.30 + pressure fall at 12.30 + pressure fall at 14.30 + pressure fall at 16.00) 4
This gives effectively equal weight to the 4 applanation readings. Mean and median difference between 'overall pressure falls' for atenolol 4%, and for adrenaline 1 % were then calculated and the odds assessed against chance as the explanation for any discrepancy between them and zero, the latter being expected from the null hypothesis that atenolol 4% and adrenaline 1 % are equally effective in reducing ocular tension.
Results PART 1 Fig. 1 Fig. 2 ) is significantly greater after atenolol drops 4% than after Eppy drops 1 % there was also some indication that it was superior to adrenaline followed by atenolol (Fig. 4) . Response to adrenaline alone did not differ markedly from the response to atenolol-then-adrenaline or adrenaline-then-atenolol.
Discussion
This study related only to a 1-day and 1-dose doublemasked carefully randomised trial so that no conclusions can be made about long-term treatment during which the effect of continued atenolol and adrenaline might decline. That is, without long-term studies we cannot claim that atenolol should replaceadrenaline. After the start of the trial it was realised that a possible bias existed in favour of atenolol as an ocular hypotensive agent to the detriment of adrenaline. Patients had often had long-continued treatment with adrenaline before the trial, but none of the early cases of course had had atenolol. Tolerance to adrenaline in spite of 36 hours' withdrawal group.bmj.com on June 7, 2017 -Published by http://bjo.bmj.com/ Downloaded from might well cause a poorer response to that drug than would be observed in an eye previously unexposed to adrenaline. However, in fact some patients had never previously had adrenaline (Nos. 1, 3, 7, 9, 11, 12) . In order to achieve greater equality in later patients atenolol drops 40% 3 times a day
were prescribed for about a month so that their eyes would not be completely fresh to the drug. Wilcoxon matched pair signed ranks test), but atenolol alone may also be superior to adrenaline-then-atenolol. The other differences (atenolol-then-adrenaline minus adrenaline-then-atenolol; adrenaline minus adrenalinethen-atenolol; adrenaline minus atenolol-then-adrenaline) were not significant x = Possibly biased in favour of atenolol because pre-and inter.
test treatment included adrenaline but not atenolol.
Inspection of Fig. 2 (see key) suggests, however, that this possible objection to the validity of our conclusions is not substantial. The mode of action of the n-blockers is just as unknown as that of adrenaline. Because of the relatively greater potency systemically (Elliot et al., 1975) than topically (Phillips et al., 1976 (Phillips et al., , 1977 an effect on production of aqueous humour was suggested. In the case of timolol maleate (a f1 and P, blocker), which has presumably a similar mode of action, there is some evidence from tonography that it reduces production of aqueous humour (Zimmerman et al., 1977) .
Ideally, new patients with open-angle glaucoma and high ocular tension who had never been previously treated should have been used in this study; such a group would have taken very many months to accumulate. Most of our presently reported patients do not have high pressures, so that we suspect that the differences we have observed may underestimate the situation which would occur in open-angle glaucoma. Also it was a small disadvantage of this group that 2 patients with unilateral glaucoma and 3 others with closed-angle glaucoma (operated on) were included, but it is interesting that the latter cases showed falls in pressure.
The simplifying second hypothesis tested in this investigation received no support. The recent observation that a r1 and 32 blocker, timolol maleate, reduces ocular tension (Zimmerman and Kaufman, 1977a, b) group.bmj.com on June 7, 2017 -Published by http://bjo.bmj.com/ Downloaded from 1971). Although we are as ignorant of the mechanism of action of the 3 blockers as we are of adrenergic agonists, these drugs can still be considered for use in the treatment of glaucoma, subject to long-term studies of effectiveness and toxicity. 
